Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis

Background: Patients with indolent systemic mastocytosis (ISM), a clonal mast cell disease primarily driven by the KIT D816V mutation, often have lifelong debilitating symptoms. Anaphylaxis is a common feature of the disease seen in up to half of patients. The effects of KIT D816V-targeted therapy o...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Thanai Pongdee, MD, Mariana Castells, MD, PhD, Cem Akin, MD, Ingunn Dybedal, MD, PhD, Jason Gotlib, MD, Jens Peter Panse, MD, Ivan Alvarez-Twose, MD, PhD, Cristina Morales Cabeza, MD, Sonia Cerquozzi, MD, FRCPC, Peter Vadas, MD, Vidushi Swarup, MS, Pankit Vachhani, MD, Friederike Wortmann, MD, Cecilia Arana Yi, MD, Ilda Bidollari, MD, Kate Newberry, PhD, Daniel Shaheen, PharmD, Karin Hartmann, MD
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2026-04-01
Cyfres:	World Allergy Organization Journal
Pynciau:	Anaphylaxis Indolent systemic mastocytosis Avapritinib
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S1939455126001857
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!